ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.68
0.69%
US Tech 100
20,500.80
0.45%
S&P 500
5,868.55
-0.22%
US Dollar vs CAD
1.43955
-0.07%
Bitcoin
96,454.91
-0.46%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) News

GNPX

Genprex (GNPX)

Genprex Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GNPX
DateTimeSourceHeadlineSymbolCompany
12/20/20247:45AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
12/16/20248:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
12/16/20248:15AMPR Newswire (US)Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
12/06/20244:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
12/06/20244:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
12/06/20244:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
12/06/20244:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
11/20/20248:29AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
11/20/20248:29AMPR Newswire (US)Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung CancerNASDAQ:GNPXGenprex Inc
11/19/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
11/13/20248:16AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
11/08/20244:00PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
11/05/20248:29AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
11/05/20248:29AMPR Newswire (US)Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingNASDAQ:GNPXGenprex Inc
10/31/20248:29AMPR Newswire (US)Genprex to Participate in 2024 BIO Europe ConferenceNASDAQ:GNPXGenprex Inc
10/28/20248:29AMPR Newswire (US)Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and GlioblastomaNASDAQ:GNPXGenprex Inc
10/24/202411:23AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GNPXGenprex Inc
10/24/20248:29AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
10/24/20248:29AMPR Newswire (US)Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK PositiveNASDAQ:GNPXGenprex Inc
10/22/202411:01AMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GNPXGenprex Inc
10/15/20248:29AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
10/15/20248:29AMPR Newswire (US)Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
10/10/20248:29AMPR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:GNPXGenprex Inc
10/07/20248:29AMPR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingNASDAQ:GNPXGenprex Inc
09/26/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
09/23/20248:29AMPR Newswire (US)Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and DiabetesNASDAQ:GNPXGenprex Inc
09/19/20248:29AMPR Newswire (US)Genprex Announces Formation of Mesothelioma Clinical Advisory BoardNASDAQ:GNPXGenprex Inc
09/09/20248:29AMPR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:GNPXGenprex Inc
09/04/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
09/04/20248:29AMPR Newswire (US)Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 DiabetesNASDAQ:GNPXGenprex Inc
 Showing the most relevant articles for your search:NASDAQ:GNPX

Your Recent History

USOTC
ASII
Accredited Solutions (PK)
NASDAQ
TSLA
Tesla
USOTC
QNCCF
Quantum eMotion (QB)
USOTC
FDCT
FDCTech (CE)
USOTC
IQST
iQSTEL (QX)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
PSRU
Valiant Eagle (PK)
USOTC
AFFU
Affluence (PK)
NASDAQ
NVDA
NVIDIA
USOTC
FNMA
Fannie Mae (QB)
USOTC
CEOS
CeCors (PK)
USOTC
RSPI
RespireRx Pharmaceuticals (CE)
USOTC
APRU
Apple Rush (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
COOP
Mr Cooper
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads